PCP
ALLO icon

Proficio Capital Partners’s Allogene Therapeutics ALLO Stock Holding History

Proficio Capital Partners’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-15
Closed – – 1933
2019
Q1 		$0 Buy
+15
New +$435 ﹤0.01% 1680

Other funds holding ALLO

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
VM
VV Manager Boston, Massachusetts $114M AUM 59.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Proficio Capital Partners's ALLO Position: Q2 2019 in Review

Proficio Capital Partners sold out of Allogene Therapeutics (ALLO) in Q2 2019, closing a stake of 15 shares.

Proficio Capital Partners first reported a position in ALLO in Q1 2019 and held it in 1 quarter. The position peaked at $0 in Q1 2019. 94 funds tracked by Wall St. Rank hold ALLO as of Q2 2019.

  • Proficio Capital Partners reported no remaining Allogene Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Proficio Capital Partners sold 15 Allogene Therapeutics shares in Q2 2019.
  • Proficio Capital Partners first reported a position in Allogene Therapeutics in Q1 2019 and held it in 1 quarter.
  • Proficio Capital Partners's Allogene Therapeutics position peaked at $0 in Q1 2019.
  • 94 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2019.

Based on Proficio Capital Partners's 13F filing for Q2 2019, filed 13 Aug 2019.